{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T16:19:42Z","timestamp":1776701982638,"version":"3.51.2"},"reference-count":24,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2006,7,21]],"date-time":"2006-07-21T00:00:00Z","timestamp":1153440000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2007,1]]},"abstract":"<jats:sec><jats:title>Aim<\/jats:title><jats:p>To compare the pharmacokinetics\/pharmacodynamics, antibiotic resistance and clinical efficacy of continuous (CA) <jats:italic>vs.<\/jats:italic> intermittent administration (IA) of cefotaxime in patients with obstructive pulmonary disease and respiratory infections.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A randomized controlled prospective nonblinded study was performed in 93 consecutive hospitalized patients requiring antibiotics for acute exacerbations of chronic obstructive pulmonary disease. Forty\u2010seven patients received 2\u2003g of cefotaxime intravenously over 24\u2003h plus a loading dose of 1\u2003g, and 46 patients were given the drug intermittently (1\u2003g three times daily).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Similar pathogens were identified in both groups, being mostly <jats:italic>Haemophilus influenzae<\/jats:italic> (51%), <jats:italic>Streptococcus pneumoniae<\/jats:italic> (21%) and <jats:italic>Moraxella catharralis<\/jats:italic> (18%). Mean minimal inhibitory concentration (MIC) values were also similar before and after treatment in both groups. Clinical cure was achieved in 37\/40 (93%) (CA) <jats:italic>vs.<\/jats:italic> 40\/43 (93%) (IA) of patients (<jats:italic>P\u2003<\/jats:italic>=\u20030.93). In microbiologically evaluable patients, criteria such as 70% of treatment time with antibiotic concentrations \u2265\u200aMIC (CA 100%<jats:italic>vs.<\/jats:italic> IA 60% of patients) and\/or \u2265\u200a5\u2003\u00d7\u2003MIC (CA 100%<jats:italic>vs.<\/jats:italic> IA 55% of patients) were significantly better following continuous administration (<jats:italic>P\u2003<\/jats:italic>&lt;\u20030.01). Samples with suboptimal antibiotic concentrations were found in 0% of CA <jats:italic>vs.<\/jats:italic> 65% of IA patients (<jats:italic>P\u2003<\/jats:italic>&lt;\u20030.01).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Although clinical cure rates were comparable, continuous cefotaxime administration led to significantly greater proportions of concentrations &gt;\u200aMIC and &gt;\u200a5\u2003\u00d7\u2003MIC compared with intermittent dosing. Continuous administration of cefotaxime at a lower dose [2\u2003g (CA) <jats:italic>vs.<\/jats:italic> 3\u2003g (CI)] is equally effective pharmacodynamically and microbiologically, may be more cost\u2010effective and offers at least the same clinical efficacy. Based on these observations, we recommend continuous administration of cefotaxime as the preferred mode of administration.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1365-2125.2006.02730.x","type":"journal-article","created":{"date-parts":[[2006,7,21]],"date-time":"2006-07-21T09:30:49Z","timestamp":1153474249000},"page":"100-109","source":"Crossref","is-referenced-by-count":47,"title":["Continuous <i>vs.<\/i> intermittent cefotaxime administration in patients with chronic obstructive pulmonary disease and respiratory tract infections: pharmacokinetics\/pharmacodynamics, bacterial susceptibility and clinical efficacy"],"prefix":"10.1111","volume":"63","author":[{"given":"A. R. H.","family":"Van Zanten","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Oudijk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. K. E.","family":"Nohlmans\u2010Paulssen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y. G.","family":"Van Der Meer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. R. J.","family":"Girbes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. H.","family":"Polderman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,7,21]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199835050-00004"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/514622"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2672.92.5s1.10.x"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.11.2914"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1469-0691.8.s.2.4.x"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0891-5520(03)00065-5"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1470-9465.2004.00863.x"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.5.931"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(01)00120-7"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro798"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1469-0691.8.s.3.3.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/00075198-200310000-00011"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00075198-200310000-00012"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(02)00316-X"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.119.2_suppl.405S"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/43.2.309"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg111"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1186\/cc2388"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02478-8"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)07366-X"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-199511000-00004"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199937040-00005"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199040040-00008"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.10.2057"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2006.02730.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2006.02730.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T21:12:26Z","timestamp":1697404346000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2006.02730.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7,21]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["10.1111\/j.1365-2125.2006.02730.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2006.02730.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,7,21]]}}}